Substance P receptor antagonists in the therapy of migraine.
about
Migraine-like episodic pain behavior in a dog: can dogs suffer from migraines?Migraine pathogenesis and state of pharmacological treatment optionsRPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks.Therapies in development for the treatment of migraine.Triptans attenuate capsaicin-induced CREB phosphorylation within the trigeminal nucleus caudalis: a mechanism to prevent central sensitization?Substance P is responsible for physiological alterations such as increased chloride ion secretion and glucose malabsorption in cryptosporidiosis.Acupoint injection of onabotulinumtoxin A for migraines.Migraine and patent foramen ovale: A residual coincidence or a pathophysiological intrigue?Migraine: emerging treatment options for preventive and acute attack therapy.Metabotropic glutamate receptor 5: a target for migraine therapy.Dual action of neurokinin-1 antagonists on Mas-related GPCRs.Botulinum toxin type a therapy in migraine: preclinical and clinical trials.Histamine in migraine and brain.An update on migraine: current understanding and future directions.Pathophysiology of Migraine: A Disorder of Sensory Processing.Implications of MRGPRX2 in human and experimental cardiometabolic diseases.Voltage-dependent calcium channels are involved in neurogenic dural vasodilatation via a presynaptic transmitter release mechanism.Activation of iGluR5 kainate receptors inhibits neurogenic dural vasodilatation in an animal model of trigeminovascular activation.Triptan-induced latent sensitization: a possible basis for medication overuse headache.Large conductance calcium-activated potassium channels (BKCa) modulate trigeminovascular nociceptive transmission.Tactile-induced ultrasonic vocalization in the rat: a novel assay to assess anti-migraine therapies in vivo.Do 5HT1B/1D receptor agonists have an effect on mood and anxiety disorders?Migraine Therapy: Current Approaches and New Horizons.
P2860
Q27025136-6018838F-868F-4C71-A873-27F45AA546A0Q30886663-DA330959-1ECA-45B0-B12D-2E9FAD7D6C31Q34648375-F49FFE6B-D851-4CE6-872F-D0B01913382EQ35011915-2F309FAA-C81D-4D13-A110-EC27B1767C36Q35113494-0C69B448-8CDD-4014-B86D-BBD7DC5D9B0FQ35689531-5F8E8CDB-A836-4C89-9882-DBE52906FF5BQ36329577-6631685B-4F94-4F71-990E-B1C594CF9DF4Q36473672-02F24F54-1809-460E-B4F7-A92F7ED179B4Q36580576-32710C4E-3B92-4A48-AA31-DB80E412A395Q37208487-4B3673DD-D3FA-4262-A7F5-ECB539012FF3Q37316211-5A5879D1-A267-4574-811A-B4EFCBF99D9AQ37631993-BDA977B9-DA52-4450-B06D-EF0FEC1669E6Q38179055-74EFAC8E-0839-4AE5-AE90-024BD2CEA090Q38742593-D4716950-1FC5-4959-866D-E9B907EC339DQ39127073-EA531CC1-C498-4ABA-B3D5-C236EEAEC662Q41103541-6FD3C21C-0E38-40E6-9D26-611E30F37056Q42151308-73385442-CE78-4264-8FE6-506BF4834A31Q43097964-CB4DB3D3-D757-43B7-B874-2B3986E07142Q43107488-A61F5F70-4C79-408C-8890-A30DF20A8464Q43242903-71EB021D-2E1D-4A5E-A2BF-946EE08A710EQ46580205-CCD75014-F896-43DF-A342-9E5CDC31EC41Q48194523-C976EAE6-A778-4BEF-BED6-DFA89D3ED50AQ52581504-C96D30FF-2C57-44D9-B531-10806E6ED395
P2860
Substance P receptor antagonists in the therapy of migraine.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Substance P receptor antagonists in the therapy of migraine.
@ast
Substance P receptor antagonists in the therapy of migraine.
@en
Substance P receptor antagonists in the therapy of migraine.
@nl
type
label
Substance P receptor antagonists in the therapy of migraine.
@ast
Substance P receptor antagonists in the therapy of migraine.
@en
Substance P receptor antagonists in the therapy of migraine.
@nl
prefLabel
Substance P receptor antagonists in the therapy of migraine.
@ast
Substance P receptor antagonists in the therapy of migraine.
@en
Substance P receptor antagonists in the therapy of migraine.
@nl
P1476
Substance P receptor antagonists in the therapy of migraine.
@en
P2093
P304
P356
10.1517/13543784.10.4.673
P407
P577
2001-04-01T00:00:00Z